SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Su-Kil Seo, Dae-Il Seo, Won Sun Park, Won-Kyo Jung, Dae-Sung Lee, Sae-Gwang Park, Jung Sik Choi, Mi-Seon Kang, Young Hyun Choi, Inhak Choi, Byeng Chul Yu, Il-Whan Choi, Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta12,14-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway, Life Sciences, 2014, 112, 1-2, 82

    CrossRef

  2. 2
    Locke J. Bryan, Leo I. Gordon, Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy, Blood Reviews, 2014,

    CrossRef

  3. 3
    R D Harvey, Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer, Clinical Pharmacology & Therapeutics, 2014, 96, 2, 214

    CrossRef

  4. 4
    Holger Krönig, Lukas Kremmler, Bernhard Haller, Carsten Englert, Christian Peschel, Reinhard Andreesen, Christian U. Blank, Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment, European Journal of Haematology, 2014, 92, 3
  5. 5
    E. B. Belai, C. E. de Oliveira, T. H. Gasparoto, R. N. Ramos, S. A. Torres, G. P. Garlet, K. A. Cavassani, J. S. Silva, A. P. Campanelli, PD-1 blockage delays murine squamous cell carcinoma development, Carcinogenesis, 2014, 35, 2, 424

    CrossRef

  6. 6
    Dagmar Quandt, Simon Jasinski-Bergner, Ulrike Müller, Bianca Schulze, Barbara Seliger, Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation, Journal of Translational Medicine, 2014, 12, 1, 151

    CrossRef

  7. 7
    Sehar Afreen, Said Dermime, The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone, Hematology/Oncology and Stem Cell Therapy, 2014, 7, 1, 1

    CrossRef

  8. 8
    Thomas E. Stinchcombe, Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy, Medical Oncology, 2014, 31, 5

    CrossRef

  9. 9
    Odey C. Ukpo, Wade L. Thorstad, James S. Lewis, B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Head and Neck Pathology, 2013, 7, 2, 113

    CrossRef

  10. 10
    Simone P Sittig, Tania Køllgaard, Kirsten Grønbæk, Manja Idorn, Jörg Hennenlotter, Arnulf Stenzl, Cécile Gouttefangeas, Per thor Straten, Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes, OncoImmunology, 2013, 2, 9, e26014

    CrossRef

  11. 11
    Rachel Lubong Sabado, Nina Bhardwaj, Dendritic cell immunotherapy, Annals of the New York Academy of Sciences, 2013, 1284, 1
  12. 12
    L. L. Cunha, M. A. Marcello, E. C. Morari, S. Nonogaki, F. F. Conte, R. Gerhard, F. A. Soares, J. Vassallo, L. S. Ward, Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation, Endocrine Related Cancer, 2013, 20, 1, 103

    CrossRef

  13. 13
    Alexei Shimanovsky, Ashif Jethava, Constantin A Dasanu, Immune alterations in malignant melanoma and current immunotherapy concepts, Expert Opinion on Biological Therapy, 2013, 13, 10, 1413

    CrossRef

  14. 14
    Bruno Bockorny, Constantin A Dasanu, Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches, Expert Opinion on Biological Therapy, 2013, 13, 6, 911

    CrossRef

  15. 15
    David F. McDermott, Michael B. Atkins, PD-1 as a potential target in cancer therapy, Cancer Medicine, 2013, 2, 5
  16. 16
    Stefani Spranger, Thomas Gajewski, Rational combinations of immunotherapeutics that target discrete pathways, Journal for ImmunoTherapy of Cancer, 2013, 1, 1, 16

    CrossRef

  17. 17
    Julien Fourcade, Hassane M. Zarour, Strategies to reverse melanoma-induced T-cell dysfunction, Clinics in Dermatology, 2013, 31, 3, 251

    CrossRef

  18. 18
    Joel Crespo, Haoyu Sun, Theodore H Welling, Zhigang Tian, Weiping Zou, T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Current Opinion in Immunology, 2013, 25, 2, 214

    CrossRef

  19. 19
    Mitra Dowlatshahi, Victor Huang, Ahmed E Gehad, Ying Jiang, Adam Calarese, Jessica E Teague, Andrew A Dorosario, Jingwei Cheng, Paul Nghiem, Carl F Schanbacher, Manisha Thakuria, Chrysalyne D Schmults, Linda C Wang, Rachael A Clark, Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses, Journal of Investigative Dermatology, 2013, 133, 7, 1879

    CrossRef

  20. 20
    Mario Sznol, Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents, Seminars in Oncology, 2012, 39, 2, 192

    CrossRef

  21. 21
    Vladimir Holec, Sona Ciernikova, Lenka Wachsmannova, Zuzana Adamcikova, Katarina Hainova, Michal Mego, Viola Stevurkova, Ludovit Danihel, Anna Liskova, Vladimir Zajac, Analysis of bacteria from intestinal tract of FAP patients for the presence of APC-like sequences, Medical Science Monitor, 2012, 18, 8, CR486

    CrossRef

  22. 22
    Juan Ma, Yoshihiko Usui, Takeshi Kezuka, Yoko Okunuki, Lina Zhang, Xiaoming An, Atsushi Mizota, Hiroshi Goto, Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1, Experimental Eye Research, 2012, 96, 1, 98

    CrossRef

  23. 23
    R Omori, J Eguchi, K Hiroishi, S Ishii, A Hiraide, M Sakaki, H Doi, A Kajiwara, T Ito, M Kogo, M Imawari, Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors, Cancer Gene Therapy, 2012, 19, 9, 637

    CrossRef

  24. 24
    Axel Bex, Tamara Etto, Florry Vyth-Dreese, Christian Blank, Arjan W. Griffioen, Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?, Current Oncology Reports, 2012, 14, 3, 230

    CrossRef

  25. 25
    Sebastian Bauer, Heinz Schmidberger, Uwe Trefzer, Individualisierte Tumortherapie und Status quo beim Melanom, Onkologie, 2012, 35, s2, 2

    CrossRef

  26. 26
    Süleyman Bayram, Hikmet Akkız, Yakup Ülger, Aynur Bekar, Ersin Akgöllü, Selçuk Yıldırım, Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case–control study, Gene, 2012, 511, 2, 308

    CrossRef

  27. 27
    Holger Krönig, Kathrin Julia Falchner, Marcus Odendahl, Bettina Brackertz, Heinke Conrad, Dieter Muck, Rüdiger Hein, Christian Blank, Christian Peschel, Bernhard Haller, Stephan Schulz, Helga Bernhard, PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease, International Journal of Cancer, 2012, 130, 10
  28. 28
    S. Viganò, M. Perreau, G. Pantaleo, A. Harari, Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  29. 29
    Axel Bex, Tom Powles, Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when, Expert Review of Anticancer Therapy, 2012, 12, 6, 787

    CrossRef

  30. 30
    Anna I. Hooijkaas, Jules Gadiot, Martin van der Valk, Wolter J. Mooi, Christian U. Blank, Targeting BRAFV600E in an Inducible Murine Model of Melanoma, The American Journal of Pathology, 2012, 181, 3, 785

    CrossRef

  31. 31
    Ana Carrizosa Anderson, Tim-3, a negative regulator of anti-tumor immunity, Current Opinion in Immunology, 2012, 24, 2, 213

    CrossRef

  32. 32
    Hyo Jin Park, Anthony Kusnadi, Eun-Jung Lee, Won Woo Kim, Byoung Chul Cho, Ik Jae Lee, Jinsil Seong, Sang-Jun Ha, Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors, Cellular Immunology, 2012, 278, 1-2, 76

    CrossRef

  33. 33
    Maciej Grzywnowicz, Krzysztof Giannopoulos, Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach, Acta Haematologica Polonica, 2012, 43, 2, 132

    CrossRef

  34. 34
    Zhen Gao, Stella E. Tsirka, Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis, Neurology Research International, 2011, 2011, 1

    CrossRef

  35. You have free access to this content35
    Cancer immunotherapy: Progress and challenges in the clinical setting, European Journal of Immunology, 2011, 41, 6
  36. 36
    Martin Loos, Rupert Langer, Tibor Schuster, Ralf Gertler, Axel Walch, Sandra Rauser, Helmut Friess, Marcus Feith, Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma, The Annals of Thoracic Surgery, 2011, 91, 4, 1025

    CrossRef

  37. 37
    Kaori Sakuishi, Pushpa Jayaraman, Samuel M. Behar, Ana C. Anderson, Vijay K. Kuchroo, Emerging Tim-3 functions in antimicrobial and tumor immunity, Trends in Immunology, 2011, 32, 8, 345

    CrossRef

  38. 38
    Bill G. Richendollar, Brad Pohlman, Paul Elson, Eric D. Hsi, Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Human Pathology, 2011, 42, 4, 552

    CrossRef

  39. 39
    Chuan-Yong Mu, Jian-An Huang, Ying Chen, Cheng Chen, Xue-Guang Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Medical Oncology, 2011, 28, 3, 682

    CrossRef

  40. 40
    Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre Van der Bruggen, Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines, Cancers, 2011, 3, 4, 2904

    CrossRef

  41. 41
    Jacalyn Rosenblatt, David F. McDermott, Immunotherapy for Renal Cell Carcinoma, Hematology/Oncology Clinics of North America, 2011, 25, 4, 793

    CrossRef

  42. 42
    Jules Gadiot, Anna I. Hooijkaas, Andrew D. M. Kaiser, Harm van Tinteren, Hester van Boven, Christian Blank, Overall survival and PD-L1 expression in metastasized malignant melanoma, Cancer, 2011, 117, 10
  43. 43
    Zhang Hua, Dalin Li, Gao Xiang, Fengyan Xu, Guan Jie, Zhenkun Fu, Zhang Jie, Pang Da, Dianjun Li, PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China, Breast Cancer Research and Treatment, 2011, 129, 1, 195

    CrossRef

  44. 44
    Maxime Chapon, Clotilde Randriamampita, Eve Maubec, Cécile Badoual, Stéphane Fouquet, Shu-Fang Wang, Eduardo Marinho, David Farhi, Marylène Garcette, Simon Jacobelli, Alexandre Rouquette, Agnès Carlotti, Angélique Girod, Armelle Prévost-Blondel, Alain Trautmann, Marie-Françoise Avril, Nadège Bercovici, Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes, Journal of Investigative Dermatology, 2011, 131, 6, 1300

    CrossRef

  45. 45
    Amal Hasan, Hazem Ghebeh, Cynthia Lehe, Rasheed Ahmad, Said Dermime, Therapeutic targeting of B7-H1 in breast cancer, Expert Opinion on Therapeutic Targets, 2011, 15, 10, 1211

    CrossRef

  46. 46
    Liancai Wang, Qingyong Ma, Xiangli Chen, Kun Guo, Junhui Li, Min Zhang, Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma, World Journal of Surgery, 2010, 34, 5, 1059

    CrossRef

  47. 47
    Rachel Lubong Sabado, Nina Bhardwaj, Directing dendritic cell immunotherapy towards successful cancer treatment, Immunotherapy, 2010, 2, 1, 37

    CrossRef

  48. 48
    Doru T. Alexandrescu, Thomas E. Ichim, Neil H. Riordan, Francesco M. Marincola, Anna Di Nardo, Filamer D. Kabigting, Constantin A. Dasanu, Immunotherapy for Melanoma: Current Status and Perspectives, Journal of Immunotherapy, 2010, 33, 6, 570

    CrossRef

  49. 49
    Charles G. Drake, Immunotherapy for Prostate Cancer: An Emerging Treatment Modality, Urologic Clinics of North America, 2010, 37, 1, 121

    CrossRef

  50. 50
    Lisa Borkner, Andrew Kaiser, Willeke van de Kasteele, Reinhard Andreesen, Andreas Mackensen, John B. Haanen, Ton N. Schumacher, Christian Blank, RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells, Cancer Immunology, Immunotherapy, 2010, 59, 8, 1173

    CrossRef

  51. 51
    W. Hobo, F. Maas, N. Adisty, T. de Witte, N. Schaap, R. van der Voort, H. Dolstra, siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells, Blood, 2010, 116, 22, 4501

    CrossRef

  52. 52
    K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, A. C. Anderson, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, Journal of Experimental Medicine, 2010, 207, 10, 2187

    CrossRef

  53. 53
    Lana E. Kandalaft, Nathan Singh, John B. Liao, Andrea Facciabene, Jonathan S. Berek, Daniel J. Powell, George Coukos, The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade, Gynecologic Oncology, 2010, 116, 2, 222

    CrossRef

  54. 54
    Ryosuke Hino, Kenji Kabashima, Yu Kato, Hiroaki Yagi, Motonobu Nakamura, Tasuku Honjo, Taku Okazaki, Yoshiki Tokura, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 2010, 116, 7
  55. 55
    Gregory Driessens, Justin Kline, Thomas F. Gajewski, Costimulatory and coinhibitory receptors in anti-tumor immunity, Immunological Reviews, 2009, 229, 1
  56. 56
    Yonghua Wang, Qianyuan Zhuang, Siwei Zhou, Zhiquan Hu, Ruzhu Lan, Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance, Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 1, 77

    CrossRef

  57. 57
    Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell, Immunotherapy of cancer, European Journal of Pharmacology, 2009, 625, 1-3, 41

    CrossRef

  58. 58
    Christina Stoeckle, Anne-Kathrin Gleske, Immunotherapy: from basic research to clinical applications, Cancer Immunology, Immunotherapy, 2009, 58, 7, 1129

    CrossRef

  59. 59
    J. Kuball, B. Hauptrock, V. Malina, E. Antunes, R.-H. Voss, M. Wolfl, R. Strong, M. Theobald, P. D. Greenberg, Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain, Journal of Experimental Medicine, 2009, 206, 2, 463

    CrossRef

  60. 60
    T Kozako, M Yoshimitsu, H Fujiwara, I Masamoto, S Horai, Y White, M Akimoto, S Suzuki, K Matsushita, K Uozumi, C Tei, N Arima, PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients, Leukemia, 2009, 23, 2, 375

    CrossRef

  61. 61
    M. Ahmadzadeh, L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White, S. A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 2009, 114, 8, 1537

    CrossRef

  62. 62
    Yu Liu, Bin Zeng, Zhuohan Zhang, Yuan Zhang, Rongcun Yang, B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer, Clinical Immunology, 2008, 129, 3, 471

    CrossRef

  63. 63
    Martin Loos, Nathalia A. Giese, Jörg Kleeff, Thomas Giese, Matthias M. Gaida, Frank Bergmann, Melanie Laschinger, Markus W.Büchler, Helmut Friess, Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer, Cancer Letters, 2008, 268, 1, 98

    CrossRef

  64. 64
    W.J. Lesterhuis, E.H.J.G. Aarntzen, I.J.M. De Vries, D.H. Schuurhuis, C.G. Figdor, G.J. Adema, C.J.A. Punt, Dendritic cell vaccines in melanoma: From promise to proof?, Critical Reviews in Oncology/Hematology, 2008, 66, 2, 118

    CrossRef

  65. 65
    Paula A. Velilla, Carlos J. Montoya, Alvaro Hoyos, Maria E. Moreno, Claire Chougnet, Maria T. Rugeles, Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newborns’ dendritic cells, Clinical Immunology, 2008, 126, 3, 243

    CrossRef

  66. 66
    G C Prendergast, Immune escape as a fundamental trait of cancer: focus on IDO, Oncogene, 2008, 27, 28, 3889

    CrossRef

  67. 67
    A. Siva, H. Xin, F. Qin, D. Oltean, K. S. Bowdish, A. Kretz-Rommel, Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200, Cancer Immunology, Immunotherapy, 2008, 57, 7, 987

    CrossRef

  68. 68
    Julien Fourcade, Pavol Kudela, Pedro A. Andrade Filho, Bratislav Janjic, Stephanie R. Land, Cindy Sander, Arthur Krieg, Albert Donnenberg, Hongmei Shen, John M. Kirkwood, Hassane M. Zarour, Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients, Journal of Immunotherapy, 2008, 31, 8, 781

    CrossRef

  69. 69
    D. Schrama, A. Hauschild, J.C. Becker, Immunmodulierende Antikörper in der Dermatoonkologie, Der Hautarzt, 2008, 59, 10, 806

    CrossRef

  70. 70
    Nicole M Haynes, Robbert G van der Most, Richard A Lake, Mark J Smyth, Immunogenic anti-cancer chemotherapy as an emerging concept, Current Opinion in Immunology, 2008, 20, 5, 545

    CrossRef

  71. 71
    Weiping Zou, Lieping Chen, Inhibitory B7-family molecules in the tumour microenvironment, Nature Reviews Immunology, 2008, 8, 6, 467

    CrossRef

  72. 72
    Barbara Seliger, Francesco M. Marincola, Soldano Ferrone, Hinrich Abken, The complex role of B7 molecules in tumor immunology, Trends in Molecular Medicine, 2008, 14, 12, 550

    CrossRef

  73. 73
    M. Schuchmann, R. G. Meyer, E. Distler, E. Von Stebut, J. Kuball, E. Schnürer, T. Wölfel, M. Theobald, A. Konur, S. Gregor, O. Schreiner, C. Huber, P. R. Galle, G. Otto, W. Herr, The Programmed Death (PD)-1/PD-Ligand 1 Pathway Regulates Graft-Versus-Host-Reactive CD8 T Cells After Liver Transplantation, American Journal of Transplantation, 2008, 8, 11
  74. 74
    Annelie Vulink, Kristen J. Radford, Cornelis Melief, Derek N.J. Hart, 2008,

    CrossRef

  75. 75
    Yuanyuan Zha, Thomas F. Gajewski, An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells, Cellular Immunology, 2007, 247, 2, 95

    CrossRef

  76. 76
    Louis M. Weiner, Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer, Nature Reviews Cancer, 2007, 7, 9, 701

    CrossRef

  77. 77
    Christian Blank, Andreas Mackensen, Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion, Cancer Immunology, Immunotherapy, 2007, 56, 5, 739

    CrossRef

  78. 78
    Diego O. Croci, Mariano F. Zacarías Fluck, María J. Rico, Pablo Matar, Gabriel A. Rabinovich, O. Graciela Scharovsky, Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment, Cancer Immunology, Immunotherapy, 2007, 56, 11, 1687

    CrossRef

  79. 79
    Shane J. F. Cronin, Josef M. Penninger, From T-cell activation signals to signaling control of anti-cancer immunity, Immunological Reviews, 2007, 220, 1
  80. 80
    Andrew T Parsa, James S Waldron, Amith Panner, Courtney A Crane, Ian F Parney, Jeffrey J Barry, Kristine E Cachola, Joseph C Murray, Tarik Tihan, Michael C Jensen, Paul S Mischel, David Stokoe, Russell O Pieper, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, 2007, 13, 1, 84

    CrossRef

  81. 81
    J. Andrew Carlson, Gerald P. Linette, Andrew Aplin, Bernard Ng, Andrzej Slominski, Melanocyte Receptors: Clinical Implications and Therapeutic Relevance, Dermatologic Clinics, 2007, 25, 4, 541

    CrossRef

  82. 82
    Lydie Trautmann, Elias A Said, Rabih Halwani, Loury Janbazian, Nicolas Chomont, Mohamed El-Far, Gaëlle Breton, Elias K Haddad, Rafick-Pierre Sekaly, Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections, Current Opinion in HIV and AIDS, 2007, 2, 3, 219

    CrossRef

  83. 83
    R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, J. S. Weber, Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, International Immunology, 2007, 19, 10, 1223

    CrossRef

  84. 84
    Steven J. O'Day, Omid Hamid, Walter J. Urba, Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), Cancer, 2007, 110, 12
  85. 85
    Dallas B. Flies, Lieping Chen, The New B7s: Playing a Pivotal Role in Tumor Immunity, Journal of Immunotherapy, 2007, 30, 3, 251

    CrossRef

  86. 86
    James L. Riley, Carl H. June, The road to recovery: translating PD-1 biology into clinical benefit, Trends in Immunology, 2007, 28, 2, 48

    CrossRef

  87. 87
    Gabriel A. Rabinovich, Thomas F. Gajewski, Cancer Immunotherapy, 2007,

    CrossRef

  88. 88
    Bruno Quesnel, Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?, Expert Review of Vaccines, 2006, 5, 6, 773

    CrossRef